Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.

BeiGene's Brukinsa beats Imbruvica in top-line progression-free survival results from the Phase III head-to-head ALPINE trial in chronic lymphocytic leukemia or small lymphocytic lymphoma, marking the first time a rival BTK inhibitor has bested the same-class standard of care in this setting, and lifting the shares of other Chinese biotechs.

With the expectation for increasing amounts of patient experience data comes the need for the FDA and sponsors to consider, and account for, the degree to which open-label bias influences oncology trial PROs; agency staff suggest trial design elements and analytic approaches for dealing with bias at a meeting on cancer clinical outcomes assessments.

French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.